Glaucoma Open-angle
📧 Sign up to get email alerts when something new happens for Glaucoma Open-angle.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-03-24EMA Authorised: Roclanda (Latanoprost;netarsudil mesilate) — Santen Oy
The European Medicines Agency has authorised Roclanda, a fixed-dose combination of latanoprost and netarsudil mesilate, for use in open-angl…
-
EMA approval · 2026-02-09EMA Authorised: Azopt (brinzolamide) — Novartis Europharm Limited
EMA authorised Azopt, brinzolamide 1% suspension, for open-angle glaucoma and ocular hypertension in the European Union. Novartis Europharm …
-
EMA approval · 2026-01-23EMA Authorised: Simbrinza (brinzolamide;brimonidine tartrate) — Novartis Europharm Limited
The EMA authorised Simbrinza, a fixed-dose combination of brinzolamide and brimonidine tartrate, for the treatment of ocular hypertension an…
-
EMA approval · 2025-01-27EMA Authorised: Izba (travoprost) — Novartis Europharm Limited
The European Medicines Agency authorised Izba, a travoprost eye drop by Novartis Europharm Limited, for ocular hypertension and open-angle g…
-
EMA approval · 2024-02-13EMA Authorised: Catiolanze (Latanoprost) — Santen Oy
EMA authorises Catiolanze (latanoprost) for glaucoma, open-angle, indicating market entry by Santen Oy.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.